Icodextrin

Summary

Icodextrin (CHEMBL1201472) is an approved unknown; indicated across 3 conditions including congestive heart failure and chronic kidney disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 3 conditions
• Clinical trials: 20

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201472
Name	Icodextrin
Type	Unknown
Max phase	4

Also known as: Extraneal, Icodextrin, Icodextrina, Icodextrine, ICODEXTRIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
congestive heart failure	3	MONDO:0005009	EFO:0000373
chronic kidney disease	2	MONDO:0005300	EFO:0003884

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 20.

Phase distribution

Phase	Trials
PHASE4	7
Not specified	5
PHASE3	3
PHASE2	3
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00397358	PHASE4	WITHDRAWN	Effect of Extraneal (Icodextrin)on Triglyceride Levels in PD Patients
NCT00567489	PHASE4	COMPLETED	IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients
NCT00725517	PHASE4	COMPLETED	Efficacy and Safety of a 7.5% Icodextrin Peritoneal Dialysis Solution in Once-Daily Long Dwell Exchange
NCT01021878	PHASE4	COMPLETED	Study to Evaluate the Effects Icodextrin Versus Dianeal on Insulin Resistance in Nondiabetic Automated Peritoneal Dialysis Patients
NCT01044446	PHASE4	COMPLETED	Effect of Icodextrin on the Treatment Outcome of Peritoneal Dialysis Patients During Acute Peritonitis
NCT01228279	PHASE4	COMPLETED	Sympathetic Activity in Patients With End-stage Renal Disease on Peritoneal Dialysis
NCT01944852	PHASE4	COMPLETED	Efficacy and Safety of a Double Icodextrin Dose in Elderly Incident CAPD Patients on Incremental PD.
NCT00567398	PHASE3	COMPLETED	IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients
NCT01124227	PHASE3	TERMINATED	Peritoneal Dialysis in Congestive Heart Failure
NCT01219959	PHASE3	COMPLETED	Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients
NCT00368641	PHASE2	TERMINATED	Heart Failure and Peritoneal Ultrafiltration
NCT01242904	PHASE2	COMPLETED	Use of a Bimodal Solution for Peritoneal Dialysis
NCT04086212	PHASE2	WITHDRAWN	Ultrafiltration Efficacy of a PD Solution Containing Icodextrin-Xylitol-Carnitine
NCT00597662	PHASE1	COMPLETED	Safety Study of Polylactide-Caprolactone-Trimethylenecarbonate Copolymer for Post-Operative Adhesion Prophylaxis
NCT05185999	PHASE1	COMPLETED	Icodextrin Study to Test Short-Term Safety, Tolerability and Preliminary Efficacy of Sodium-Free Solution in PD Patients
NCT06552546	Not specified	NOT_YET_RECRUITING	Pharmacokinetics of Single- and Double-dose Icodextrin
NCT00119990	Not specified	TERMINATED	Changes in Cardiovascular Hemodynamics During Peritoneal Dialysis
NCT01119196	Not specified	COMPLETED	The Measurement of Insulin Resistance in Peritoneal Dialysis Patients
NCT02166359	Not specified	COMPLETED	Effect of Extraneal (Icodextrin) on Triglyceride Levels in PD Patients
NCT02318888	Not specified	UNKNOWN	Does Icodextrin Reduce the Risk of Small Bowel Obstruction?

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).